# Epilepsy GTx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epilepsy-gtx

- Industry: Biotechnology
- Headquarters: Canterbury, UK
- Website: www.epilepsygtx.com
- Total disclosed funding: $43M
- Latest round: Series A (Dec 10, 2025)
- Investors on record: 4

## About

Established in 2022 and based in Cambridge, UK, Epilepsy GTx operates as a late preclinical stage biotechnology research company that develops gene therapy for the treatment of seizures in patients. In December 2025, Epilepsy GTx Limited raised USD 33 million in series A funding from new investors XGEN Venture and British Business Bank, with participation from other unspecified investors.

EpilepsyGTx develops gene therapies for focal refractory epilepsy (FRE). Their primary offering, EPY201, aims to provide seizure freedom for patients whose seizures persist despite treatment with multiple antiseizure medications. Moreover, EPY201 utilizes an AAV9 capsid to deliver a transgene encoding an engineered Kv1.1 potassium channel, which reduces neuronal excitability and epileptic activity. The company's approach involves the targeted delivery of gene therapy to the specific area of the brain where seizures originate. 

The company will use the December 2025 funding to advance gene therapy programs, support clinical trials, and expand manufacturing capabilities.

## Funding rounds

- Series A, Dec 10, 2025, $33M — British Business Bank, XGEN Venture
- Seed, Jun 24, 2024, $10M — UCL Technology Fund, Health Technology Holding

## Investors

- UCL Technology Fund (https://capitalatlas.ai/funds/ucl-technology-fund) — Seed
- Health Technology Holding (https://capitalatlas.ai/funds/health-technology-holding) — Seed
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series A
- XGEN Venture (https://capitalatlas.ai/funds/xgen-venture) — Series A